Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals, 56103-56104 [2018-24485]
Download as PDF
<![CDATA[
56103
Federal Register / Vol. 83, No. 218 / Friday, November 9, 2018 / Notices
On March 27, 2012, 3D PDF filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on April 20, 2012 (77 FR 23754).
The last notification was filed with
the Department on August 15, 2018. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on September 4, 2018 (83 FR
44904).
Suzanne Morris,
Chief, Premerger and Division Statistics Unit,
Antitrust Division.
[FR Doc. 2018–24542 Filed 11–8–18; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
ACTION:
Notice of registration.
The registrant listed below
has applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of various classes of
schedule I and II controlled substances.
SUPPLEMENTARY INFORMATION: The
company listed below applied to be
registered as bulk manufacturer of
various basic classes of controlled
substances. Information on the
previously published notice is listed in
the table below. No comments or
objections were submitted for this
notice.
SUMMARY:
Company
FR citation
Euticals Inc ...
83 FR 39129
Published
August 8,
2018.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of this registrant to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed company.
Dated: October 29, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–24484 Filed 11–8–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Chattem
Chemicals
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 8, 2019.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated
his authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on August
2, 2018, Chattem Chemicals, 3801 Saint
Elmo Avenue, Chattanooga, Tennessee
37409–1237 applied to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
khammond on DSK30JT082PROD with NOTICES
Controlled substance
Drug code
Gamma Hydroxybutyric Acid ...................................................................................................................................
Marihuana ................................................................................................................................................................
Tetrahydrocannabinols ............................................................................................................................................
4-Methoxyamphetamine ..........................................................................................................................................
Dihydromorphine .....................................................................................................................................................
Amphetamine ..........................................................................................................................................................
Methamphetamine ...................................................................................................................................................
Lisdexamfetamine ...................................................................................................................................................
Methylphenidate ......................................................................................................................................................
Codeine ...................................................................................................................................................................
Dihydrocodeine ........................................................................................................................................................
Oxycodone ..............................................................................................................................................................
Hydromorphone .......................................................................................................................................................
Hydrocodone ...........................................................................................................................................................
Levorphanol .............................................................................................................................................................
Methadone ...............................................................................................................................................................
Methadone intermediate ..........................................................................................................................................
Morphine ..................................................................................................................................................................
Oripavine .................................................................................................................................................................
Thebaine ..................................................................................................................................................................
Oxymorphone ..........................................................................................................................................................
Noroxymorphone .....................................................................................................................................................
VerDate Sep<11>2014
17:36 Nov 08, 2018
Jkt 247001
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
E:\FR\FM\09NON1.SGM
09NON1
2010
7360
7370
7411
9145
1100
1105
1205
1724
9050
9120
9143
9150
9193
9220
9250
9254
9300
9330
9333
9652
9668
Schedule
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
56104
Federal Register / Vol. 83, No. 218 / Friday, November 9, 2018 / Notices
Controlled substance
Drug code
Tapentadol ...............................................................................................................................................................
Fentanyl ...................................................................................................................................................................
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers.
In reference to drug code 7360
(marihuana) and 7370
(tetrahydrocannabinols) the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
Dated: October 25, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–24485 Filed 11–8–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1105–0025]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension
Without Change, of a Previously
Approved Collection; Federal Coal
Lease Request
Antitrust Division, Department
of Justice.
ACTION: 30-Day notice.
AGENCY:
The Department of Justice
(DOJ), Antitrust Division (ATR), will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 30 days until
December 10, 2018.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Jill Ptacek, Attorney, Antitrust Division,
United States Department of Justice, 450
Fifth Street NW, Suite 8000,
Washington, DC 20530 (phone: 202–
307–6607).
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
khammond on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:36 Nov 08, 2018
Jkt 247001
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of Information Collection:
Extension of a currently approved
collection.
2. The Title of the Form/Collection:
Federal Coal Lease Reserves.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The form numbers are ATR–139 and
ATR–140. The applicable component
within the Department of Justice is the
Antitrust Division.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: Business or other for profit.
Other: None. The Department of Justice
evaluates the competitive impact of
issuances, transfers and exchanges of
federal coal leases. These forms seek
information regarding a prospective coal
lessee’s existing coal reserves. The
Department uses this information to
determine whether the issuance,
transfer or exchange of the federal coal
lease is consistent with the antitrust
laws.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 10
respondents will complete each form,
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
9780
9801
Schedule
II
II
with each response taking
approximately two hours.
6. An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated 20
annual burden hours associated with
this collection, in total.
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, Suite 3E.405B,
Washington, DC 20530.
Dated: November 6, 2018.
Melody Braswell,
Department Clearance Officer, PRA, U.S.
Department of Justice.
[FR Doc. 2018–24544 Filed 11–8–18; 8:45 am]
BILLING CODE 4410–12–P
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Consent Decree Under the Clean Water
Act
On October 31, 2018, the Department
of Justice lodged a proposed Consent
Decree with the United States District
Court for the Western District of
Louisiana in the lawsuit entitled United
States and Louisiana Department of
Environmental Quality v. Evangeline
Enterprises LLC, Civil Action No. 17–
01340.
In this action, the United States, on
behalf of the U.S. Environmental
Protection Agency, together with the
Louisiana Department of Environmental
Quality (‘‘LDEQ’’), sought penalties and
injunctive relief under the Clean Water
Act and the Louisiana Environmental
Quality Act against Evangeline
Enterprises LLC (‘‘Evangeline’’) for
continuous unauthorized discharges of
pollutants from Evangeline’s race horse
training facility in Carencro, Louisiana
to waters of the United States and
waters of the State of Louisiana. The
proposed Consent Decree will resolve
the claims alleged by the United States
and LDEQ and requires Evangeline to
pay $300,000 in civil penalties and
perform injunctive relief to bring its
facility into compliance with applicable
federal and state laws and regulations to
prevent future discharges to area
waterways.
E:\FR\FM\09NON1.SGM
09NON1
]]>Agencies
[Federal Register Volume 83, Number 218 (Friday, November 9, 2018)]
[Notices]
[Pages 56103-56104]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-24485]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Chattem
Chemicals
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before January 8, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the
Controlled Substances Act to the Administrator of the Drug Enforcement
Administration (DEA), 28 CFR 0.100(b). Authority to exercise all
necessary functions with respect to the promulgation and implementation
of 21 CFR part 1301, incident to the registration of manufacturers,
distributors, dispensers, importers, and exporters of controlled
substances (other than final orders in connection with suspension,
denial, or revocation of registration) has been redelegated to the
Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on August
2, 2018, Chattem Chemicals, 3801 Saint Elmo Avenue, Chattanooga,
Tennessee 37409-1237 applied to be registered as a bulk manufacturer of
the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid....... 2010 I
Marihuana....................... 7360 I
Tetrahydrocannabinols........... 7370 I
4-Methoxyamphetamine............ 7411 I
Dihydromorphine................. 9145 I
Amphetamine..................... 1100 II
Methamphetamine................. 1105 II
Lisdexamfetamine................ 1205 II
Methylphenidate................. 1724 II
Codeine......................... 9050 II
Dihydrocodeine.................. 9120 II
Oxycodone....................... 9143 II
Hydromorphone................... 9150 II
Hydrocodone..................... 9193 II
Levorphanol..................... 9220 II
Methadone....................... 9250 II
Methadone intermediate.......... 9254 II
Morphine........................ 9300 II
Oripavine....................... 9330 II
Thebaine........................ 9333 II
Oxymorphone..................... 9652 II
Noroxymorphone.................. 9668 II
[[Page 56104]]
Tapentadol...................... 9780 II
Fentanyl........................ 9801 II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution and sale to its customers.
In reference to drug code 7360 (marihuana) and 7370
(tetrahydrocannabinols) the company plans to bulk manufacture these
drugs as synthetic. No other activities for these drug codes are
authorized for this registration.
Dated: October 25, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-24485 Filed 11-8-18; 8:45 am]
BILLING CODE 4410-09-P
